Clinical trials: Herpes Zoster, active
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Cardiovascular Disease
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
This study is designed to evaluate whether the adjuvanted recombinant zoster vaccine (RZV) or the adjuvanted respiratory syncytial virus PreFusion protein 3 (RSVPreF3) vaccine can attenuate the progression of coronary plaque in…
- Trial name
- NCT07712380
- Testing
- Adjuvanted RZV vaccine, Adjuvanted RSVPreF3 vaccine
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older
The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.
- Trial name
- NCT06447779
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- 4 sites in China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Shingles, Herpes Zoster
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 764 healthy adults.
- Conditions
- Shingles, Herpes Zoster, Vaccine-Preventable Diseases
- Trial name
- NCT06569823
- Testing
- Z-1018, Shingrix
- Where
- 16 sites in Australia, New Zealand
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Herpes Zoster
A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)
The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete…
- Trial name
- NCT07293065
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- 4 sites in China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Cardiovascular Disease, Dementia
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults.
- Trial name
- DAN-ZOSTER (NCT07485283)
- Testing
- Recombinant Herpes Zoster Vaccine (Shingrix)
- Where
- 2 sites in Denmark
- Volunteers
- 168,460 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Herpes Zoster
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
Background: Shingles is a painful, blistering rash caused by the same virus that causes chickenpox. Shingrix is a vaccine approved to prevent shingles in healthy adults over age 50 and in immunocompromised adults over age 18.
- Trial name
- NCT05580458
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster (HZ)
Obesity and Obesity-Related Factors and Risk of Herpes Zoster (Shingles) and Postherpetic Neuralgia
The investigators' objectives are to examine the longitudinal association of obesity and obesity-related factors and risk of incident herpes zoster (HZ), also known as shingles, and the longitudinal association of obesity and…
- Trial name
- NCT06638177
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Vaccine, Varicella-zoster Virus
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
Immunocompromised individuals, such as patients with multiple sclerosis (MS) or diseases of the neuromyelitis optica spectrum (NMOSD) treated with an anti-CD20 monoclonal antibody, present an increased risk of shingles.
- Conditions
- Vaccine, Varicella-zoster Virus, Multiple Sclerosis, Spectrum Disease Neuromyelitis Optica
- Trial name
- TACTIC (NCT07818356)
- Testing
- Two-dose M0-M2 vaccination schedule, Two-dose M0-M6 vaccination schedule
- Where
- 24 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Toulouse
Herpes Zoster, Pain
The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ) and represents a major clinical challenge due to its chronicity and impact on quality of life.
- Conditions
- Herpes Zoster, Pain, Postherpetic Neuralgia
- Trial name
- NCT07361796
- Testing
- Venlafaxine combined conventional therapy, Conventional therapy
- Where
- China
- Volunteers
- 832 people
- Sponsor
- Beijing Tiantan Hospital
Herpes Zoster Pain
Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain
This is a randomized, prospective, multicenter, open-label, blinded-endpoint study investigating the efficacy and safety of dexamethasone palmitate (DXP) for treating acute and subacute herpes zoster (shingles) pain.
- Trial name
- NCT07344246
- Testing
- intravenous infusion with 4 mg dexamethasone palmitate or 8 mg dexamethasone palmitate
- Where
- China
- Volunteers
- 954 people
- Sponsor
- Beijing Tiantan Hospital
Kidney Transplant; Complications, Varicella Zoster Virus Infection
Herpes Virus Infections in Kidney Transplant Patients
Kidney transplant recipients are at increased risk of infections, including Varicella-zoster virus (VZV) infections. Vaccination against VZV is routinely offered to all kidney transplant recipients and candidates in Denmark.
- Conditions
- Kidney Transplant; Complications, Varicella Zoster Virus Infection, Vaccine-Preventable Diseases
- Trial name
- HINT (NCT05604911)
- Where
- 5 sites in Denmark
- Volunteers
- 280 people
- Sponsor
- Susanne Dam Nielsen, MD, DMSc
Midpoint Transverse Process to Pleura Block, Erector Spinae Plane Block
Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain
The aim of this study is to compare the analgesic efficacy and safety of ultrasound-guided midpoint transverse process block versus ultrasound-guided erector spinae plane block in patients suffering from thoracic herpes zoster…
- Conditions
- Midpoint Transverse Process to Pleura Block, Erector Spinae Plane Block, Acute Herpes Zoster, Pain
- Trial name
- NCT07732556
- Testing
- Midpoint transverse process to pleura block, Erector spinae plane block
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Tanta University
Calcitonin, Subcutaneous
Subcutaneous Calcitonin in Acute Herpes Zoster
This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.
- Conditions
- Calcitonin, Subcutaneous, Acute Herpes Zoster
- Trial name
- NCT07655804
- Testing
- Calcitonin, Saline
- Where
- Egypt
- Volunteers
- 168 people
- Sponsor
- Tanta University
Follicular Lymphoma
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular Lymphoma requiring treatment…
- Trial name
- FIL_FollVax22 (NCT06070961)
- Testing
- Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus
- Where
- 14 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Acute Herpes Zoster
Efficacy of Electroacupuncture for Acute Herpes Zoster-Associated Pain and Biomarker Evaluation
Background: Herpes zoster (HZ) is an acute dermatological condition caused by the varicella-zoster virus. Its onset is characterized by severe pain, imposing significant physical and psychological burdens on patients.
- Trial name
- NCT07515885
- Testing
- Acupuncture, Valacyclovir, pregabalin and mecobalamin
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Dexiong Han
Vaccine Reaction, Zoster
Reduced Vaccine Response to HZ/su in SLE
The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without…
- Conditions
- Vaccine Reaction, Zoster, Systemic Lupus Erythematosus
- Trial name
- NCT07636044
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Herpes Zoster
Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine
This is a multicenter retrospective cohort study to evaluate the long-term effectiveness of the live attenuated herpes zoster vaccine within 6 years after vaccination.
- Trial name
- NCT07585370
- Testing
- Attenuated Zoster Vaccine, Live
- Where
- China
- Volunteers
- 24,740 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Herpes Zoster
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland.
- Trial name
- NCT07502560
- Testing
- Recombinant zoster vaccine
- Where
- 8 sites in Finland
- Volunteers
- 33,609 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Spondylitis, Ankylosing
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
Introduction: Patients with autoimmune rheumatic diseases (ARDs), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PAs), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), primary…
- Conditions
- Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus Erythematosus
- Trial name
- RZVRheum (NCT05879419)
- Testing
- Recombinant Herpes Zoster Vaccine (RZV), MTX Discontinuation, MMF Discontinuation
- Where
- Brazil
- Volunteers
- 2,005 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital